Diagnosis and management of inflammatory bowel disease in children.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28566467.
- Also identified by DOI 10.1136/bmj.j2083 and PMC identifier 6888256.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are lifelong conditions that often begin in childhood. The implications of IBD are of particular importance in children because of the potential negative effects on growth, development, psychosocial function, and overall wellbeing. The key management strategy is to achieve sustained control of intestinal inflammation and monitor for potential complications of the disease and side effects of therapies. Overall, the evidence on the management of IBD in children is less extensive than in adults, but good quality multicenter studies and various guidelines and society consensus statements are available. This review summarizes the evidence on the pathophysiology, diagnosis, and approaches to management of children and adolescents with IBD.
Medical subject headings
- Age of Onset
- Anti-Bacterial Agents
- Anti-Bacterial Agents/therapeutic use
- Biomarkers
- Biomarkers/blood
- Child
- Endoscopy, Gastrointestinal
- Endoscopy, Gastrointestinal/methods
- Evidence-Based Medicine
- Gastrointestinal Agents
- Gastrointestinal Agents/therapeutic use
- Genetic Predisposition to Disease
- Humans
- Immunosuppressive Agents
- Immunosuppressive Agents/therapeutic use
- Inflammatory Bowel Diseases
- Inflammatory Bowel Diseases/diagnosis
- Inflammatory Bowel Diseases/drug therapy
- Inflammatory Bowel Diseases/physiopathology